Regeneron Pharmaceuticals Inc (REGN) : Two Sigma Advisers Lp reduced its stake in Regeneron Pharmaceuticals Inc by 3.8% during the most recent quarter end. The investment management company now holds a total of 387,180 shares of Regeneron Pharmaceuticals Inc which is valued at $163,211,857 after selling 15,300 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Regeneron Pharmaceuticals Inc makes up approximately 0.79% of Two Sigma Advisers Lp’s portfolio.
Other Hedge Funds, Including , Bamco Inc Ny reduced its stake in REGN by selling 2,452 shares or 32.86% in the most recent quarter. The Hedge Fund company now holds 5,011 shares of REGN which is valued at $2,112,337. Regeneron Pharmaceuticals Inc makes up approx 0.01% of Bamco Inc Ny’s portfolio. Stevens Capital Management Lp added REGN to its portfolio by purchasing 7,364 company shares during the most recent quarter which is valued at $3,104,221. Regeneron Pharmaceuticals Inc makes up approx 0.12% of Stevens Capital Management Lp’s portfolio. Columbia Partners L L C Investment Management sold out all of its stake in REGN during the most recent quarter. The investment firm sold 17,324 shares of REGN which is valued $7,302,759. Dynamic Technology Lab Private Ltd added REGN to its portfolio by purchasing 706 company shares during the most recent quarter which is valued at $297,607. Regeneron Pharmaceuticals Inc makes up approx 0.08% of Dynamic Technology Lab Private Ltd’s portfolio. Parametrica Management Ltd sold out all of its stake in REGN during the most recent quarter. The investment firm sold 1,120 shares of REGN which is valued $438,301.
Regeneron Pharmaceuticals Inc opened for trading at $394.75 and hit $394.75 on the upside on Thursday, eventually ending the session at $393.4, with a gain of 0.22% or 0.85 points. The heightened volatility saw the trading volume jump to 4,79,344 shares. Company has a market cap of $41,423 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.